- Home
- RARE vs GEO Comparison
RARE vs GEO Comparison
Compare RARE & GEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RARE | GEO |
|---|---|---|
| Founded | 2010 | 1984 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Homebuilding |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.0B |
| IPO Year | 2013 | 1996 |
Fundamental Metrics
Financial Performance| Metric | RARE | GEO |
|---|---|---|
| Price | $21.26 | $14.40 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 19 | 3 |
| Target Price | ★ $66.32 | $39.67 |
| AVG Volume (30 Days) | 2.0M | ★ 2.5M |
| Earning Date | 05-04-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 7.31 | ★ 727.27 |
| EPS | N/A | ★ 1.82 |
| Revenue | $673,000,000.00 | ★ $2,263,420,000.00 |
| Revenue This Year | $13.40 | $13.89 |
| Revenue Next Year | $42.83 | $11.68 |
| P/E Ratio | ★ N/A | $8.21 |
| Revenue Growth | ★ 20.13 | 3.85 |
| 52 Week Low | $18.41 | $12.51 |
| 52 Week High | $40.54 | $32.09 |
Technical Indicators
Market Signals| Indicator | RARE | GEO |
|---|---|---|
| Relative Strength Index (RSI) | 37.40 | 43.36 |
| Support Level | $19.61 | $14.27 |
| Resistance Level | $25.46 | $17.35 |
| Average True Range (ATR) | 0.98 | 0.83 |
| MACD | 0.03 | 0.11 |
| Stochastic Oscillator | 39.06 | 62.38 |
Price Performance
Historical ComparisonAbout RARE Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.
About GEO Geo Group Inc (The) REIT
The GEO Group Inc specializes in detention facilities and community reentry centers. It operates in four segments: U.S. Secure Services, which mainly encompasses U.S.-based secure services business; Electronic Monitoring and Supervision Services, which conducts its services in the United States, represents services provided to adults for monitoring services and evidence-based supervision and treatment programs for community-based parolees, probationers, and pretrial defendants; Reentry Services conducts its services in the United States represents services provided to adults for residential and non-residential treatment, educational and community-based programs, pre-release and half-way house programs; and International Services.